nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—breast cancer	0.118	1	CbGaD
Cladribine—Azacitidine—Gemcitabine—breast cancer	0.0952	0.512	CrCrCtD
Cladribine—Decitabine—Gemcitabine—breast cancer	0.0907	0.488	CrCrCtD
Cladribine—POLE—Gemcitabine—breast cancer	0.0755	0.19	CbGbCtD
Cladribine—NR5A1—Vinblastine—breast cancer	0.0599	0.151	CbGbCtD
Cladribine—RRM1—Gemcitabine—breast cancer	0.0502	0.126	CbGbCtD
Cladribine—RRM2—Gemcitabine—breast cancer	0.0502	0.126	CbGbCtD
Cladribine—POLA1—Gemcitabine—breast cancer	0.0434	0.109	CbGbCtD
Cladribine—SLC28A3—Gemcitabine—breast cancer	0.0434	0.109	CbGbCtD
Cladribine—DCK—Gemcitabine—breast cancer	0.0267	0.0672	CbGbCtD
Cladribine—NR5A1—corpus luteum—breast cancer	0.00793	0.126	CbGeAlD
Cladribine—ABCG2—Tamoxifen—breast cancer	0.00661	0.0166	CbGbCtD
Cladribine—ABCG2—Mitoxantrone—breast cancer	0.00644	0.0162	CbGbCtD
Cladribine—SLC22A2—Vinblastine—breast cancer	0.00611	0.0154	CbGbCtD
Cladribine—ABCG2—Paclitaxel—breast cancer	0.00514	0.0129	CbGbCtD
Cladribine—ABCG2—Irinotecan—breast cancer	0.00507	0.0128	CbGbCtD
Cladribine—ABCG2—Fluorouracil—breast cancer	0.00487	0.0122	CbGbCtD
Cladribine—ABCG2—Carboplatin—breast cancer	0.00484	0.0122	CbGbCtD
Cladribine—ABCG2—Docetaxel—breast cancer	0.00372	0.00935	CbGbCtD
Cladribine—ABCG2—Doxorubicin—breast cancer	0.00277	0.00697	CbGbCtD
Cladribine—ABCG2—Methotrexate—breast cancer	0.00268	0.00675	CbGbCtD
Cladribine—POLE4—embryo—breast cancer	0.00178	0.0284	CbGeAlD
Cladribine—POLE2—embryo—breast cancer	0.00156	0.0248	CbGeAlD
Cladribine—POLE4—skin of body—breast cancer	0.00138	0.022	CbGeAlD
Cladribine—POLE3—mammary gland—breast cancer	0.00127	0.0202	CbGeAlD
Cladribine—POLE2—endometrium—breast cancer	0.00114	0.0182	CbGeAlD
Cladribine—RRM2B—nipple—breast cancer	0.00111	0.0177	CbGeAlD
Cladribine—POLE4—female reproductive system—breast cancer	0.00108	0.0172	CbGeAlD
Cladribine—POLE3—nipple—breast cancer	0.00105	0.0167	CbGeAlD
Cladribine—SLC28A3—nipple—breast cancer	0.000981	0.0156	CbGeAlD
Cladribine—POLE—mammary gland—breast cancer	0.000967	0.0154	CbGeAlD
Cladribine—POLE2—adrenal gland—breast cancer	0.000922	0.0147	CbGeAlD
Cladribine—POLE4—endocrine gland—breast cancer	0.000915	0.0146	CbGeAlD
Cladribine—POLE2—bone marrow—breast cancer	0.000892	0.0142	CbGeAlD
Cladribine—POLE3—embryo—breast cancer	0.000865	0.0138	CbGeAlD
Cladribine—POLE2—female gonad—breast cancer	0.00086	0.0137	CbGeAlD
Cladribine—POLA1—mammary gland—breast cancer	0.000833	0.0133	CbGeAlD
Cladribine—POLE—nipple—breast cancer	0.0008	0.0127	CbGeAlD
Cladribine—RRM2—mammary gland—breast cancer	0.000796	0.0127	CbGeAlD
Cladribine—RRM2B—endometrium—breast cancer	0.00067	0.0107	CbGeAlD
Cladribine—PNP—uterus—breast cancer	0.000665	0.0106	CbGeAlD
Cladribine—RRM1—mammary gland—breast cancer	0.000662	0.0105	CbGeAlD
Cladribine—POLE—embryo—breast cancer	0.00066	0.0105	CbGeAlD
Cladribine—POLE3—endometrium—breast cancer	0.000633	0.0101	CbGeAlD
Cladribine—RRM2B—pituitary gland—breast cancer	0.000606	0.00965	CbGeAlD
Cladribine—RRM2B—adipose tissue—breast cancer	0.000604	0.00961	CbGeAlD
Cladribine—PNP—female reproductive system—breast cancer	0.000598	0.00952	CbGeAlD
Cladribine—POLE3—pituitary gland—breast cancer	0.000573	0.00912	CbGeAlD
Cladribine—POLE3—adipose tissue—breast cancer	0.000571	0.00908	CbGeAlD
Cladribine—PNP—bone marrow—breast cancer	0.000564	0.00898	CbGeAlD
Cladribine—NR5A1—pituitary gland—breast cancer	0.000555	0.00884	CbGeAlD
Cladribine—RRM2B—female reproductive system—breast cancer	0.000555	0.00883	CbGeAlD
Cladribine—POLE2—lymph node—breast cancer	0.000553	0.0088	CbGeAlD
Cladribine—RRM1—nipple—breast cancer	0.000547	0.00871	CbGeAlD
Cladribine—PNP—female gonad—breast cancer	0.000544	0.00866	CbGeAlD
Cladribine—RRM2—embryo—breast cancer	0.000543	0.00865	CbGeAlD
Cladribine—RRM2B—adrenal gland—breast cancer	0.000541	0.00862	CbGeAlD
Cladribine—SLC28A3—adipose tissue—breast cancer	0.000534	0.0085	CbGeAlD
Cladribine—POLE3—female reproductive system—breast cancer	0.000524	0.00835	CbGeAlD
Cladribine—RRM2B—bone marrow—breast cancer	0.000524	0.00834	CbGeAlD
Cladribine—Azacitidine—DNMT3A—breast cancer	0.000519	0.157	CrCbGaD
Cladribine—POLE3—adrenal gland—breast cancer	0.000512	0.00815	CbGeAlD
Cladribine—NR5A1—female reproductive system—breast cancer	0.000508	0.00809	CbGeAlD
Cladribine—Decitabine—DNMT3A—breast cancer	0.000506	0.153	CrCbGaD
Cladribine—PNP—endocrine gland—breast cancer	0.000506	0.00805	CbGeAlD
Cladribine—RRM2B—female gonad—breast cancer	0.000505	0.00804	CbGeAlD
Cladribine—NR5A1—adrenal gland—breast cancer	0.000496	0.0079	CbGeAlD
Cladribine—POLE3—bone marrow—breast cancer	0.000495	0.00788	CbGeAlD
Cladribine—POLE—endometrium—breast cancer	0.000483	0.00769	CbGeAlD
Cladribine—POLE3—female gonad—breast cancer	0.000477	0.0076	CbGeAlD
Cladribine—RRM2B—endocrine gland—breast cancer	0.000469	0.00747	CbGeAlD
Cladribine—SLC28A3—bone marrow—breast cancer	0.000463	0.00738	CbGeAlD
Cladribine—Azacitidine—CDA—breast cancer	0.000462	0.14	CrCbGaD
Cladribine—NR5A1—female gonad—breast cancer	0.000462	0.00736	CbGeAlD
Cladribine—SLC28A3—female gonad—breast cancer	0.000447	0.00711	CbGeAlD
Cladribine—POLE3—endocrine gland—breast cancer	0.000444	0.00707	CbGeAlD
Cladribine—POLE—pituitary gland—breast cancer	0.000437	0.00696	CbGeAlD
Cladribine—POLE—adipose tissue—breast cancer	0.000435	0.00693	CbGeAlD
Cladribine—NR5A1—endocrine gland—breast cancer	0.00043	0.00685	CbGeAlD
Cladribine—DCK—nipple—breast cancer	0.000425	0.00677	CbGeAlD
Cladribine—RRM2—skin of body—breast cancer	0.000422	0.00672	CbGeAlD
Cladribine—POLA1—endometrium—breast cancer	0.000416	0.00663	CbGeAlD
Cladribine—POLE—female reproductive system—breast cancer	0.0004	0.00637	CbGeAlD
Cladribine—RRM2—endometrium—breast cancer	0.000398	0.00633	CbGeAlD
Cladribine—POLE—adrenal gland—breast cancer	0.00039	0.00622	CbGeAlD
Cladribine—POLE—bone marrow—breast cancer	0.000378	0.00601	CbGeAlD
Cladribine—POLA1—pituitary gland—breast cancer	0.000377	0.006	CbGeAlD
Cladribine—POLA1—adipose tissue—breast cancer	0.000375	0.00597	CbGeAlD
Cladribine—RRM2—uterus—breast cancer	0.000366	0.00584	CbGeAlD
Cladribine—POLE—female gonad—breast cancer	0.000364	0.0058	CbGeAlD
Cladribine—RRM2—pituitary gland—breast cancer	0.00036	0.00573	CbGeAlD
Cladribine—RRM2—adipose tissue—breast cancer	0.000358	0.00571	CbGeAlD
Cladribine—DCK—embryo—breast cancer	0.000351	0.00558	CbGeAlD
Cladribine—RRM1—skin of body—breast cancer	0.00035	0.00558	CbGeAlD
Cladribine—POLE—endocrine gland—breast cancer	0.000339	0.00539	CbGeAlD
Cladribine—POLA1—adrenal gland—breast cancer	0.000336	0.00536	CbGeAlD
Cladribine—RRM1—endometrium—breast cancer	0.00033	0.00526	CbGeAlD
Cladribine—RRM2—female reproductive system—breast cancer	0.000329	0.00525	CbGeAlD
Cladribine—POLA1—bone marrow—breast cancer	0.000326	0.00518	CbGeAlD
Cladribine—RRM2B—lymph node—breast cancer	0.000325	0.00517	CbGeAlD
Cladribine—RRM2—adrenal gland—breast cancer	0.000321	0.00512	CbGeAlD
Cladribine—Adenosine monophosphate—PIM1—breast cancer	0.000314	0.0948	CrCbGaD
Cladribine—POLA1—female gonad—breast cancer	0.000314	0.005	CbGeAlD
Cladribine—RRM2—bone marrow—breast cancer	0.000311	0.00495	CbGeAlD
Cladribine—POLE3—lymph node—breast cancer	0.000307	0.00488	CbGeAlD
Cladribine—RRM1—uterus—breast cancer	0.000304	0.00485	CbGeAlD
Cladribine—RRM2—female gonad—breast cancer	0.0003	0.00477	CbGeAlD
Cladribine—RRM1—pituitary gland—breast cancer	0.000299	0.00476	CbGeAlD
Cladribine—RRM1—adipose tissue—breast cancer	0.000298	0.00474	CbGeAlD
Cladribine—Azacitidine—DNMT1—breast cancer	0.00028	0.0845	CrCbGaD
Cladribine—RRM2—endocrine gland—breast cancer	0.000279	0.00444	CbGeAlD
Cladribine—RRM1—female reproductive system—breast cancer	0.000274	0.00436	CbGeAlD
Cladribine—Decitabine—DNMT1—breast cancer	0.000273	0.0825	CrCbGaD
Cladribine—Adenosine monophosphate—APRT—breast cancer	0.000267	0.0806	CrCbGaD
Cladribine—RRM1—adrenal gland—breast cancer	0.000267	0.00425	CbGeAlD
Cladribine—RRM1—bone marrow—breast cancer	0.000258	0.00411	CbGeAlD
Cladribine—RRM2—Gefitinib—Lapatinib—breast cancer	0.000258	0.0947	CbGdCrCtD
Cladribine—DCK—endometrium—breast cancer	0.000257	0.00409	CbGeAlD
Cladribine—PNP—Gefitinib—Lapatinib—breast cancer	0.000251	0.092	CbGdCrCtD
Cladribine—RRM1—female gonad—breast cancer	0.000249	0.00397	CbGeAlD
Cladribine—DCK—uterus—breast cancer	0.000236	0.00377	CbGeAlD
Cladribine—POLE2—Topotecan—Irinotecan—breast cancer	0.000236	0.0865	CbGdCrCtD
Cladribine—POLE—lymph node—breast cancer	0.000234	0.00373	CbGeAlD
Cladribine—DCK—pituitary gland—breast cancer	0.000232	0.0037	CbGeAlD
Cladribine—RRM1—endocrine gland—breast cancer	0.000232	0.00369	CbGeAlD
Cladribine—DCK—adipose tissue—breast cancer	0.000231	0.00368	CbGeAlD
Cladribine—Floxuridine—TYMS—breast cancer	0.000223	0.0673	CrCbGaD
Cladribine—DCK—female reproductive system—breast cancer	0.000213	0.00338	CbGeAlD
Cladribine—DCK—adrenal gland—breast cancer	0.000207	0.0033	CbGeAlD
Cladribine—POLA1—lymph node—breast cancer	0.000202	0.00321	CbGeAlD
Cladribine—DCK—bone marrow—breast cancer	0.000201	0.0032	CbGeAlD
Cladribine—SLC22A1—adipose tissue—breast cancer	0.000197	0.00314	CbGeAlD
Cladribine—DCK—female gonad—breast cancer	0.000193	0.00308	CbGeAlD
Cladribine—RRM2—lymph node—breast cancer	0.000193	0.00307	CbGeAlD
Cladribine—DCK—endocrine gland—breast cancer	0.00018	0.00286	CbGeAlD
Cladribine—Trifluridine—TYMS—breast cancer	0.000177	0.0535	CrCbGaD
Cladribine—RRM1—lymph node—breast cancer	0.00016	0.00255	CbGeAlD
Cladribine—SLC22A1—endocrine gland—breast cancer	0.000153	0.00244	CbGeAlD
Cladribine—ABCG2—endometrium—breast cancer	0.000143	0.00228	CbGeAlD
Cladribine—ABCG2—uterus—breast cancer	0.000132	0.0021	CbGeAlD
Cladribine—ABCG2—pituitary gland—breast cancer	0.00013	0.00206	CbGeAlD
Cladribine—ABCG2—adipose tissue—breast cancer	0.000129	0.00205	CbGeAlD
Cladribine—PNP—Paclitaxel—Docetaxel—breast cancer	0.000128	0.0468	CbGdCrCtD
Cladribine—DCK—lymph node—breast cancer	0.000124	0.00198	CbGeAlD
Cladribine—POLE2—Doxorubicin—Idarubicin—breast cancer	0.000121	0.0443	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Idarubicin—breast cancer	0.000121	0.0443	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Idarubicin—breast cancer	0.000121	0.0443	CbGdCrCtD
Cladribine—ABCG2—adrenal gland—breast cancer	0.000116	0.00184	CbGeAlD
Cladribine—ABCG2—bone marrow—breast cancer	0.000112	0.00178	CbGeAlD
Cladribine—Adenosine monophosphate—PDE4D—breast cancer	0.00011	0.0332	CrCbGaD
Cladribine—ABCG2—female gonad—breast cancer	0.000108	0.00172	CbGeAlD
Cladribine—DCK—Topotecan—Irinotecan—breast cancer	0.000106	0.039	CbGdCrCtD
Cladribine—POLA1—Vinblastine—Vinorelbine—breast cancer	9.99e-05	0.0367	CbGdCrCtD
Cladribine—Adenosine monophosphate—SRC—breast cancer	9.63e-05	0.0291	CrCbGaD
Cladribine—PNP—Daunorubicin—Idarubicin—breast cancer	9.31e-05	0.0342	CbGdCrCtD
Cladribine—RRM2—Vinorelbine—Vinblastine—breast cancer	8.44e-05	0.031	CbGdCrCtD
Cladribine—Clofarabine—ABCG2—breast cancer	8.39e-05	0.0253	CrCbGaD
Cladribine—ABCG2—lymph node—breast cancer	6.94e-05	0.0011	CbGeAlD
Cladribine—PNP—Tamoxifen—Toremifene—breast cancer	5.72e-05	0.021	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Fluoxymesterone—breast cancer	5.65e-05	0.0207	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—breast cancer	5.54e-05	0.0203	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Epirubicin—breast cancer	5.54e-05	0.0203	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Epirubicin—breast cancer	5.54e-05	0.0203	CbGdCrCtD
Cladribine—POLA1—Norethindrone—Fluoxymesterone—breast cancer	5.45e-05	0.02	CbGdCrCtD
Cladribine—DCK—Epirubicin—Idarubicin—breast cancer	5.44e-05	0.02	CbGdCrCtD
Cladribine—DCK—Doxorubicin—Idarubicin—breast cancer	5.44e-05	0.02	CbGdCrCtD
Cladribine—RRM1—Azacitidine—Gemcitabine—breast cancer	5.42e-05	0.0199	CbGdCrCtD
Cladribine—DCK—Clomifene—Toremifene—breast cancer	5.21e-05	0.0191	CbGdCrCtD
Cladribine—PNP—Testosterone Propionate—Fluoxymesterone—breast cancer	5.14e-05	0.0189	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—breast cancer	5.12e-05	0.0188	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—breast cancer	5.12e-05	0.0188	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—breast cancer	5.12e-05	0.0188	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Gemcitabine—breast cancer	4.28e-05	0.0157	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Epirubicin—breast cancer	4.27e-05	0.0157	CbGdCrCtD
Cladribine—PNP—Danazol—Fluoxymesterone—breast cancer	4.27e-05	0.0157	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Doxorubicin—breast cancer	3.95e-05	0.0145	CbGdCrCtD
Cladribine—PNP—Norethindrone—Fluoxymesterone—breast cancer	3.85e-05	0.0141	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Gemcitabine—breast cancer	3.4e-05	0.0125	CbGdCrCtD
Cladribine—DCK—Clomifene—Tamoxifen—breast cancer	3.27e-05	0.012	CbGdCrCtD
Cladribine—DCK—Desoximetasone—Fluoxymesterone—breast cancer	3.06e-05	0.0112	CbGdCrCtD
Cladribine—DCK—Doxorubicin—Epirubicin—breast cancer	2.5e-05	0.00916	CbGdCrCtD
Cladribine—DCK—Epirubicin—Doxorubicin—breast cancer	2.31e-05	0.00848	CbGdCrCtD
Cladribine—Mediastinal disorder—Methotrexate—breast cancer	1.76e-05	0.00013	CcSEcCtD
Cladribine—Rash—Mitoxantrone—breast cancer	1.75e-05	0.000129	CcSEcCtD
Cladribine—Rash—Irinotecan—breast cancer	1.75e-05	0.000129	CcSEcCtD
Cladribine—Dermatitis—Mitoxantrone—breast cancer	1.75e-05	0.000129	CcSEcCtD
Cladribine—Dermatitis—Irinotecan—breast cancer	1.75e-05	0.000129	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Docetaxel—breast cancer	1.75e-05	0.000129	CcSEcCtD
Cladribine—Chills—Methotrexate—breast cancer	1.75e-05	0.000129	CcSEcCtD
Cladribine—Headache—Mitoxantrone—breast cancer	1.74e-05	0.000129	CcSEcCtD
Cladribine—Headache—Irinotecan—breast cancer	1.74e-05	0.000129	CcSEcCtD
Cladribine—Hypotension—Capecitabine—breast cancer	1.74e-05	0.000128	CcSEcCtD
Cladribine—Insomnia—Docetaxel—breast cancer	1.74e-05	0.000128	CcSEcCtD
Cladribine—Paraesthesia—Docetaxel—breast cancer	1.72e-05	0.000127	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—breast cancer	1.72e-05	0.000127	CcSEcCtD
Cladribine—Alopecia—Methotrexate—breast cancer	1.72e-05	0.000127	CcSEcCtD
Cladribine—Vomiting—Gemcitabine—breast cancer	1.72e-05	0.000127	CcSEcCtD
Cladribine—Dyspnoea—Docetaxel—breast cancer	1.71e-05	0.000127	CcSEcCtD
Cladribine—Somnolence—Docetaxel—breast cancer	1.71e-05	0.000126	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—breast cancer	1.71e-05	0.000126	CcSEcCtD
Cladribine—Rash—Gemcitabine—breast cancer	1.71e-05	0.000126	CcSEcCtD
Cladribine—Dermatitis—Gemcitabine—breast cancer	1.7e-05	0.000126	CcSEcCtD
Cladribine—Eye disorder—Epirubicin—breast cancer	1.7e-05	0.000126	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—breast cancer	1.7e-05	0.000125	CcSEcCtD
Cladribine—Erythema—Methotrexate—breast cancer	1.7e-05	0.000125	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—breast cancer	1.7e-05	0.000125	CcSEcCtD
Cladribine—Headache—Gemcitabine—breast cancer	1.7e-05	0.000125	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Capecitabine—breast cancer	1.69e-05	0.000125	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—breast cancer	1.69e-05	0.000125	CcSEcCtD
Cladribine—Vomiting—Fluorouracil—breast cancer	1.69e-05	0.000125	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—breast cancer	1.69e-05	0.000125	CcSEcCtD
Cladribine—Insomnia—Capecitabine—breast cancer	1.68e-05	0.000124	CcSEcCtD
Cladribine—Rash—Fluorouracil—breast cancer	1.68e-05	0.000124	CcSEcCtD
Cladribine—Dermatitis—Fluorouracil—breast cancer	1.68e-05	0.000124	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—breast cancer	1.67e-05	0.000124	CcSEcCtD
Cladribine—Paraesthesia—Capecitabine—breast cancer	1.67e-05	0.000123	CcSEcCtD
Cladribine—Decreased appetite—Docetaxel—breast cancer	1.67e-05	0.000123	CcSEcCtD
Cladribine—Hypersensitivity—Paclitaxel—breast cancer	1.67e-05	0.000123	CcSEcCtD
Cladribine—Headache—Fluorouracil—breast cancer	1.67e-05	0.000123	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—breast cancer	1.67e-05	0.000123	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—breast cancer	1.66e-05	0.000123	CcSEcCtD
Cladribine—Gastrointestinal disorder—Docetaxel—breast cancer	1.66e-05	0.000123	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—breast cancer	1.66e-05	0.000122	CcSEcCtD
Cladribine—Dyspnoea—Capecitabine—breast cancer	1.66e-05	0.000122	CcSEcCtD
Cladribine—Fatigue—Docetaxel—breast cancer	1.66e-05	0.000122	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—breast cancer	1.65e-05	0.000122	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—breast cancer	1.65e-05	0.000122	CcSEcCtD
Cladribine—Nausea—Irinotecan—breast cancer	1.65e-05	0.000122	CcSEcCtD
Cladribine—Nausea—Mitoxantrone—breast cancer	1.65e-05	0.000122	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—breast cancer	1.65e-05	0.000122	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—breast cancer	1.64e-05	0.000121	CcSEcCtD
Cladribine—Pain—Docetaxel—breast cancer	1.64e-05	0.000121	CcSEcCtD
Cladribine—Constipation—Docetaxel—breast cancer	1.64e-05	0.000121	CcSEcCtD
Cladribine—Back pain—Methotrexate—breast cancer	1.64e-05	0.000121	CcSEcCtD
Cladribine—Chills—Epirubicin—breast cancer	1.64e-05	0.000121	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—breast cancer	1.63e-05	0.00012	CcSEcCtD
Cladribine—Asthenia—Paclitaxel—breast cancer	1.63e-05	0.00012	CcSEcCtD
Cladribine—Decreased appetite—Capecitabine—breast cancer	1.62e-05	0.000119	CcSEcCtD
Cladribine—Alopecia—Epirubicin—breast cancer	1.61e-05	0.000119	CcSEcCtD
Cladribine—Nausea—Gemcitabine—breast cancer	1.61e-05	0.000119	CcSEcCtD
Cladribine—Gastrointestinal disorder—Capecitabine—breast cancer	1.61e-05	0.000119	CcSEcCtD
Cladribine—Fatigue—Capecitabine—breast cancer	1.6e-05	0.000118	CcSEcCtD
Cladribine—Pruritus—Paclitaxel—breast cancer	1.6e-05	0.000118	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—breast cancer	1.6e-05	0.000118	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—breast cancer	1.59e-05	0.000118	CcSEcCtD
Cladribine—Pain—Capecitabine—breast cancer	1.59e-05	0.000117	CcSEcCtD
Cladribine—Constipation—Capecitabine—breast cancer	1.59e-05	0.000117	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—breast cancer	1.59e-05	0.000117	CcSEcCtD
Cladribine—Erythema—Epirubicin—breast cancer	1.59e-05	0.000117	CcSEcCtD
Cladribine—Feeling abnormal—Docetaxel—breast cancer	1.58e-05	0.000117	CcSEcCtD
Cladribine—Nausea—Fluorouracil—breast cancer	1.58e-05	0.000117	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—breast cancer	1.58e-05	0.000116	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—breast cancer	1.57e-05	0.000116	CcSEcCtD
Cladribine—Gastrointestinal pain—Docetaxel—breast cancer	1.57e-05	0.000116	CcSEcCtD
Cladribine—Anaemia—Methotrexate—breast cancer	1.57e-05	0.000116	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—breast cancer	1.57e-05	0.000116	CcSEcCtD
Cladribine—Flatulence—Epirubicin—breast cancer	1.56e-05	0.000116	CcSEcCtD
Cladribine—Diarrhoea—Paclitaxel—breast cancer	1.55e-05	0.000115	CcSEcCtD
Cladribine—Back pain—Epirubicin—breast cancer	1.54e-05	0.000113	CcSEcCtD
Cladribine—Feeling abnormal—Capecitabine—breast cancer	1.53e-05	0.000113	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—breast cancer	1.53e-05	0.000113	CcSEcCtD
Cladribine—Malaise—Methotrexate—breast cancer	1.53e-05	0.000113	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—breast cancer	1.52e-05	0.000113	CcSEcCtD
Cladribine—Gastrointestinal pain—Capecitabine—breast cancer	1.52e-05	0.000112	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—breast cancer	1.52e-05	0.000112	CcSEcCtD
Cladribine—Body temperature increased—Docetaxel—breast cancer	1.52e-05	0.000112	CcSEcCtD
Cladribine—Abdominal pain—Docetaxel—breast cancer	1.52e-05	0.000112	CcSEcCtD
Cladribine—Chills—Doxorubicin—breast cancer	1.51e-05	0.000112	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—breast cancer	1.51e-05	0.000111	CcSEcCtD
Cladribine—Dizziness—Paclitaxel—breast cancer	1.5e-05	0.000111	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—breast cancer	1.49e-05	0.00011	CcSEcCtD
Cladribine—Cough—Methotrexate—breast cancer	1.48e-05	0.000109	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—breast cancer	1.48e-05	0.000109	CcSEcCtD
Cladribine—Urticaria—Capecitabine—breast cancer	1.48e-05	0.000109	CcSEcCtD
Cladribine—Ill-defined disorder—Epirubicin—breast cancer	1.47e-05	0.000109	CcSEcCtD
Cladribine—Body temperature increased—Capecitabine—breast cancer	1.47e-05	0.000109	CcSEcCtD
Cladribine—Abdominal pain—Capecitabine—breast cancer	1.47e-05	0.000109	CcSEcCtD
Cladribine—Erythema—Doxorubicin—breast cancer	1.47e-05	0.000109	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—breast cancer	1.47e-05	0.000109	CcSEcCtD
Cladribine—Anaemia—Epirubicin—breast cancer	1.47e-05	0.000108	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—breast cancer	1.45e-05	0.000107	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—breast cancer	1.44e-05	0.000107	CcSEcCtD
Cladribine—Chest pain—Methotrexate—breast cancer	1.44e-05	0.000107	CcSEcCtD
Cladribine—Myalgia—Methotrexate—breast cancer	1.44e-05	0.000107	CcSEcCtD
Cladribine—Vomiting—Paclitaxel—breast cancer	1.44e-05	0.000106	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.43e-05	0.000106	CcSEcCtD
Cladribine—Malaise—Epirubicin—breast cancer	1.43e-05	0.000106	CcSEcCtD
Cladribine—Rash—Paclitaxel—breast cancer	1.43e-05	0.000106	CcSEcCtD
Cladribine—Dermatitis—Paclitaxel—breast cancer	1.43e-05	0.000105	CcSEcCtD
Cladribine—Discomfort—Methotrexate—breast cancer	1.43e-05	0.000105	CcSEcCtD
Cladribine—Back pain—Doxorubicin—breast cancer	1.42e-05	0.000105	CcSEcCtD
Cladribine—Headache—Paclitaxel—breast cancer	1.42e-05	0.000105	CcSEcCtD
Cladribine—Hypersensitivity—Docetaxel—breast cancer	1.41e-05	0.000105	CcSEcCtD
Cladribine—Confusional state—Methotrexate—breast cancer	1.4e-05	0.000103	CcSEcCtD
Cladribine—Cough—Epirubicin—breast cancer	1.38e-05	0.000102	CcSEcCtD
Cladribine—Asthenia—Docetaxel—breast cancer	1.38e-05	0.000102	CcSEcCtD
Cladribine—Infection—Methotrexate—breast cancer	1.38e-05	0.000102	CcSEcCtD
Cladribine—Hypersensitivity—Capecitabine—breast cancer	1.37e-05	0.000101	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—breast cancer	1.36e-05	0.000101	CcSEcCtD
Cladribine—Pruritus—Docetaxel—breast cancer	1.36e-05	0.0001	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—breast cancer	1.36e-05	0.0001	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—breast cancer	1.36e-05	0.0001	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—breast cancer	1.36e-05	0.0001	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—breast cancer	1.35e-05	9.98e-05	CcSEcCtD
Cladribine—Myalgia—Epirubicin—breast cancer	1.35e-05	9.98e-05	CcSEcCtD
Cladribine—Chest pain—Epirubicin—breast cancer	1.35e-05	9.98e-05	CcSEcCtD
Cladribine—Anxiety—Epirubicin—breast cancer	1.35e-05	9.95e-05	CcSEcCtD
Cladribine—Nausea—Paclitaxel—breast cancer	1.35e-05	9.94e-05	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—breast cancer	1.34e-05	9.93e-05	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.34e-05	9.92e-05	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—breast cancer	1.34e-05	9.89e-05	CcSEcCtD
Cladribine—Discomfort—Epirubicin—breast cancer	1.33e-05	9.87e-05	CcSEcCtD
Cladribine—Asthenia—Capecitabine—breast cancer	1.33e-05	9.86e-05	CcSEcCtD
Cladribine—Malaise—Doxorubicin—breast cancer	1.32e-05	9.79e-05	CcSEcCtD
Cladribine—Anorexia—Methotrexate—breast cancer	1.32e-05	9.75e-05	CcSEcCtD
Cladribine—Pruritus—Capecitabine—breast cancer	1.32e-05	9.72e-05	CcSEcCtD
Cladribine—Diarrhoea—Docetaxel—breast cancer	1.31e-05	9.71e-05	CcSEcCtD
Cladribine—Confusional state—Epirubicin—breast cancer	1.31e-05	9.65e-05	CcSEcCtD
Cladribine—Oedema—Epirubicin—breast cancer	1.3e-05	9.57e-05	CcSEcCtD
Cladribine—Hypotension—Methotrexate—breast cancer	1.29e-05	9.56e-05	CcSEcCtD
Cladribine—Infection—Epirubicin—breast cancer	1.29e-05	9.51e-05	CcSEcCtD
Cladribine—Cough—Doxorubicin—breast cancer	1.28e-05	9.47e-05	CcSEcCtD
Cladribine—Diarrhoea—Capecitabine—breast cancer	1.27e-05	9.4e-05	CcSEcCtD
Cladribine—Nervous system disorder—Epirubicin—breast cancer	1.27e-05	9.39e-05	CcSEcCtD
Cladribine—Dizziness—Docetaxel—breast cancer	1.27e-05	9.38e-05	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—breast cancer	1.27e-05	9.37e-05	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—breast cancer	1.26e-05	9.34e-05	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—breast cancer	1.26e-05	9.32e-05	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—breast cancer	1.26e-05	9.3e-05	CcSEcCtD
Cladribine—Hyperhidrosis—Epirubicin—breast cancer	1.25e-05	9.25e-05	CcSEcCtD
Cladribine—Insomnia—Methotrexate—breast cancer	1.25e-05	9.25e-05	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—breast cancer	1.25e-05	9.24e-05	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—breast cancer	1.25e-05	9.24e-05	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—breast cancer	1.25e-05	9.24e-05	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—breast cancer	1.25e-05	9.21e-05	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—breast cancer	1.24e-05	9.18e-05	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.24e-05	9.17e-05	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—breast cancer	1.24e-05	9.13e-05	CcSEcCtD
Cladribine—Anorexia—Epirubicin—breast cancer	1.23e-05	9.12e-05	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—breast cancer	1.23e-05	9.12e-05	CcSEcCtD
Cladribine—Somnolence—Methotrexate—breast cancer	1.23e-05	9.09e-05	CcSEcCtD
Cladribine—Dizziness—Capecitabine—breast cancer	1.23e-05	9.09e-05	CcSEcCtD
Cladribine—Vomiting—Docetaxel—breast cancer	1.22e-05	9.02e-05	CcSEcCtD
Cladribine—Rash—Docetaxel—breast cancer	1.21e-05	8.95e-05	CcSEcCtD
Cladribine—Hypotension—Epirubicin—breast cancer	1.21e-05	8.94e-05	CcSEcCtD
Cladribine—Dermatitis—Docetaxel—breast cancer	1.21e-05	8.94e-05	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—breast cancer	1.21e-05	8.93e-05	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—breast cancer	1.2e-05	8.89e-05	CcSEcCtD
Cladribine—Headache—Docetaxel—breast cancer	1.2e-05	8.89e-05	CcSEcCtD
Cladribine—Oedema—Doxorubicin—breast cancer	1.2e-05	8.86e-05	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—breast cancer	1.19e-05	8.83e-05	CcSEcCtD
Cladribine—Fatigue—Methotrexate—breast cancer	1.19e-05	8.82e-05	CcSEcCtD
Cladribine—Infection—Doxorubicin—breast cancer	1.19e-05	8.8e-05	CcSEcCtD
Cladribine—Pain—Methotrexate—breast cancer	1.18e-05	8.75e-05	CcSEcCtD
Cladribine—Vomiting—Capecitabine—breast cancer	1.18e-05	8.74e-05	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—breast cancer	1.18e-05	8.72e-05	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—breast cancer	1.18e-05	8.69e-05	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—breast cancer	1.17e-05	8.67e-05	CcSEcCtD
Cladribine—Rash—Capecitabine—breast cancer	1.17e-05	8.66e-05	CcSEcCtD
Cladribine—Insomnia—Epirubicin—breast cancer	1.17e-05	8.66e-05	CcSEcCtD
Cladribine—Dermatitis—Capecitabine—breast cancer	1.17e-05	8.65e-05	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—breast cancer	1.17e-05	8.64e-05	CcSEcCtD
Cladribine—Headache—Capecitabine—breast cancer	1.16e-05	8.61e-05	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—breast cancer	1.16e-05	8.6e-05	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—breast cancer	1.16e-05	8.59e-05	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—breast cancer	1.16e-05	8.56e-05	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—breast cancer	1.15e-05	8.53e-05	CcSEcCtD
Cladribine—Somnolence—Epirubicin—breast cancer	1.15e-05	8.51e-05	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—breast cancer	1.14e-05	8.44e-05	CcSEcCtD
Cladribine—Nausea—Docetaxel—breast cancer	1.14e-05	8.43e-05	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—breast cancer	1.14e-05	8.43e-05	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—breast cancer	1.13e-05	8.36e-05	CcSEcCtD
Cladribine—Decreased appetite—Epirubicin—breast cancer	1.13e-05	8.32e-05	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—breast cancer	1.12e-05	8.28e-05	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—breast cancer	1.12e-05	8.26e-05	CcSEcCtD
Cladribine—Fatigue—Epirubicin—breast cancer	1.12e-05	8.25e-05	CcSEcCtD
Cladribine—Constipation—Epirubicin—breast cancer	1.11e-05	8.19e-05	CcSEcCtD
Cladribine—Pain—Epirubicin—breast cancer	1.11e-05	8.19e-05	CcSEcCtD
Cladribine—Nausea—Capecitabine—breast cancer	1.1e-05	8.16e-05	CcSEcCtD
Cladribine—Urticaria—Methotrexate—breast cancer	1.1e-05	8.13e-05	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—breast cancer	1.09e-05	8.09e-05	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—breast cancer	1.09e-05	8.09e-05	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.09e-05	8.07e-05	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—breast cancer	1.08e-05	8.01e-05	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—breast cancer	1.08e-05	7.95e-05	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—breast cancer	1.07e-05	7.9e-05	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—breast cancer	1.07e-05	7.89e-05	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—breast cancer	1.07e-05	7.87e-05	CcSEcCtD
Cladribine—Gastrointestinal pain—Epirubicin—breast cancer	1.06e-05	7.83e-05	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—breast cancer	1.04e-05	7.7e-05	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—breast cancer	1.03e-05	7.65e-05	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—breast cancer	1.03e-05	7.64e-05	CcSEcCtD
Cladribine—Urticaria—Epirubicin—breast cancer	1.03e-05	7.6e-05	CcSEcCtD
Cladribine—Constipation—Doxorubicin—breast cancer	1.02e-05	7.57e-05	CcSEcCtD
Cladribine—Pain—Doxorubicin—breast cancer	1.02e-05	7.57e-05	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—breast cancer	1.02e-05	7.57e-05	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—breast cancer	1.02e-05	7.57e-05	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—breast cancer	1.02e-05	7.54e-05	CcSEcCtD
Cladribine—Asthenia—Methotrexate—breast cancer	9.93e-06	7.34e-05	CcSEcCtD
Cladribine—Feeling abnormal—Doxorubicin—breast cancer	9.88e-06	7.3e-05	CcSEcCtD
Cladribine—Gastrointestinal pain—Doxorubicin—breast cancer	9.8e-06	7.24e-05	CcSEcCtD
Cladribine—Pruritus—Methotrexate—breast cancer	9.79e-06	7.24e-05	CcSEcCtD
Cladribine—Hypersensitivity—Epirubicin—breast cancer	9.54e-06	7.05e-05	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—breast cancer	9.52e-06	7.04e-05	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—breast cancer	9.47e-06	7e-05	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—breast cancer	9.47e-06	7e-05	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—breast cancer	9.47e-06	7e-05	CcSEcCtD
Cladribine—Asthenia—Epirubicin—breast cancer	9.29e-06	6.87e-05	CcSEcCtD
Cladribine—Pruritus—Epirubicin—breast cancer	9.16e-06	6.77e-05	CcSEcCtD
Cladribine—Dizziness—Methotrexate—breast cancer	9.15e-06	6.76e-05	CcSEcCtD
Cladribine—Diarrhoea—Epirubicin—breast cancer	8.86e-06	6.55e-05	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—breast cancer	8.83e-06	6.53e-05	CcSEcCtD
Cladribine—Vomiting—Methotrexate—breast cancer	8.8e-06	6.5e-05	CcSEcCtD
Cladribine—Rash—Methotrexate—breast cancer	8.73e-06	6.45e-05	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—breast cancer	8.72e-06	6.44e-05	CcSEcCtD
Cladribine—Headache—Methotrexate—breast cancer	8.67e-06	6.41e-05	CcSEcCtD
Cladribine—Asthenia—Doxorubicin—breast cancer	8.6e-06	6.35e-05	CcSEcCtD
Cladribine—Dizziness—Epirubicin—breast cancer	8.57e-06	6.33e-05	CcSEcCtD
Cladribine—Pruritus—Doxorubicin—breast cancer	8.48e-06	6.27e-05	CcSEcCtD
Cladribine—Vomiting—Epirubicin—breast cancer	8.24e-06	6.09e-05	CcSEcCtD
Cladribine—Nausea—Methotrexate—breast cancer	8.22e-06	6.08e-05	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—breast cancer	8.2e-06	6.06e-05	CcSEcCtD
Cladribine—Rash—Epirubicin—breast cancer	8.17e-06	6.04e-05	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—breast cancer	8.16e-06	6.03e-05	CcSEcCtD
Cladribine—Headache—Epirubicin—breast cancer	8.11e-06	6e-05	CcSEcCtD
Cladribine—Dizziness—Doxorubicin—breast cancer	7.93e-06	5.86e-05	CcSEcCtD
Cladribine—Nausea—Epirubicin—breast cancer	7.69e-06	5.69e-05	CcSEcCtD
Cladribine—Vomiting—Doxorubicin—breast cancer	7.62e-06	5.63e-05	CcSEcCtD
Cladribine—Rash—Doxorubicin—breast cancer	7.56e-06	5.58e-05	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—breast cancer	7.55e-06	5.58e-05	CcSEcCtD
Cladribine—Headache—Doxorubicin—breast cancer	7.51e-06	5.55e-05	CcSEcCtD
Cladribine—Nausea—Doxorubicin—breast cancer	7.12e-06	5.26e-05	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—HMOX1—breast cancer	4.12e-06	4.35e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—RAF1—breast cancer	4.11e-06	4.35e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—PLG—breast cancer	4.11e-06	4.35e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPARGC1B—breast cancer	4.1e-06	4.34e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1B—breast cancer	4.08e-06	4.32e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MAPK3—breast cancer	4.08e-06	4.31e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—HMOX1—breast cancer	4.07e-06	4.31e-05	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—breast cancer	4.06e-06	4.3e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—MTHFR—breast cancer	3.97e-06	4.19e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—breast cancer	3.97e-06	4.19e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—breast cancer	3.95e-06	4.18e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA3—breast cancer	3.94e-06	4.17e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HMMR—breast cancer	3.94e-06	4.17e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCC1—breast cancer	3.94e-06	4.17e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CAV1—breast cancer	3.91e-06	4.14e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CA9—breast cancer	3.91e-06	4.14e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA4—breast cancer	3.91e-06	4.14e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—breast cancer	3.91e-06	4.13e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—breast cancer	3.89e-06	4.12e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA4—breast cancer	3.87e-06	4.09e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA9—breast cancer	3.87e-06	4.09e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MDM2—breast cancer	3.85e-06	4.07e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—RAF1—breast cancer	3.83e-06	4.05e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPARGC1B—breast cancer	3.82e-06	4.04e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPX2—breast cancer	3.81e-06	4.03e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA2—breast cancer	3.81e-06	4.03e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CD—breast cancer	3.81e-06	4.03e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—HMOX1—breast cancer	3.8e-06	4.01e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPX2—breast cancer	3.77e-06	3.99e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA2—breast cancer	3.77e-06	3.99e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1A—breast cancer	3.77e-06	3.98e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SULT1A1—breast cancer	3.77e-06	3.98e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPX4—breast cancer	3.77e-06	3.98e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ALB—breast cancer	3.76e-06	3.97e-05	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—breast cancer	3.75e-06	3.97e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SULT1A1—breast cancer	3.73e-06	3.94e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPX4—breast cancer	3.73e-06	3.94e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—IDH1—breast cancer	3.68e-06	3.89e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA1—breast cancer	3.68e-06	3.89e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—CAV1—breast cancer	3.66e-06	3.87e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—breast cancer	3.64e-06	3.85e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA1—breast cancer	3.64e-06	3.85e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—IDH1—breast cancer	3.64e-06	3.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NAT2—breast cancer	3.64e-06	3.85e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CA9—breast cancer	3.61e-06	3.82e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA4—breast cancer	3.61e-06	3.82e-05	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—breast cancer	3.6e-06	3.81e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NAT2—breast cancer	3.6e-06	3.81e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NOS3—breast cancer	3.59e-06	3.8e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK3—breast cancer	3.59e-06	3.8e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CG—breast cancer	3.57e-06	3.77e-05	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—breast cancer	3.52e-06	3.72e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPX2—breast cancer	3.52e-06	3.72e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA2—breast cancer	3.52e-06	3.72e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—breast cancer	3.49e-06	3.69e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPX4—breast cancer	3.47e-06	3.67e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SULT1A1—breast cancer	3.47e-06	3.67e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—IDH1—breast cancer	3.39e-06	3.59e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA1—breast cancer	3.39e-06	3.59e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NAT2—breast cancer	3.35e-06	3.55e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CG—breast cancer	3.33e-06	3.52e-05	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—breast cancer	3.32e-06	3.51e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CB—breast cancer	3.32e-06	3.51e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—breast cancer	3.29e-06	3.48e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK3—breast cancer	3.21e-06	3.4e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—DPYD—breast cancer	3.19e-06	3.37e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—MED12—breast cancer	3.19e-06	3.37e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MED12—breast cancer	3.16e-06	3.34e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—DPYD—breast cancer	3.16e-06	3.34e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALDOA—breast cancer	3.14e-06	3.32e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CD—breast cancer	3.13e-06	3.32e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—breast cancer	3.12e-06	3.3e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALDOA—breast cancer	3.11e-06	3.29e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ALB—breast cancer	3.09e-06	3.27e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NCOA3—breast cancer	3.05e-06	3.22e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC2A2—breast cancer	3.03e-06	3.2e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NCOA3—breast cancer	3.02e-06	3.19e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC2A2—breast cancer	2.99e-06	3.17e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CPT1A—breast cancer	2.96e-06	3.13e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—MTR—breast cancer	2.96e-06	3.13e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NOS3—breast cancer	2.96e-06	3.13e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—breast cancer	2.96e-06	3.13e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—DPYD—breast cancer	2.94e-06	3.11e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MED12—breast cancer	2.94e-06	3.11e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CPT1A—breast cancer	2.93e-06	3.1e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MTR—breast cancer	2.93e-06	3.1e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCG2—breast cancer	2.93e-06	3.1e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CD—breast cancer	2.93e-06	3.1e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HPGDS—breast cancer	2.91e-06	3.07e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALDOA—breast cancer	2.9e-06	3.06e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—ALB—breast cancer	2.89e-06	3.06e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HBA1—breast cancer	2.89e-06	3.06e-05	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—breast cancer	2.88e-06	3.04e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HPGDS—breast cancer	2.88e-06	3.04e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—breast cancer	2.87e-06	3.03e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HBA1—breast cancer	2.86e-06	3.02e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTT1—breast cancer	2.82e-06	2.98e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ACHE—breast cancer	2.82e-06	2.98e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NCOA3—breast cancer	2.81e-06	2.97e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC2A2—breast cancer	2.79e-06	2.95e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTT1—breast cancer	2.79e-06	2.95e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ACHE—breast cancer	2.79e-06	2.95e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—NOS3—breast cancer	2.77e-06	2.93e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—breast cancer	2.76e-06	2.91e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—breast cancer	2.75e-06	2.91e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CPT1A—breast cancer	2.73e-06	2.89e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MTR—breast cancer	2.73e-06	2.89e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCG2—breast cancer	2.73e-06	2.89e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CB—breast cancer	2.73e-06	2.89e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—breast cancer	2.71e-06	2.86e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HPGDS—breast cancer	2.68e-06	2.84e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP17A1—breast cancer	2.67e-06	2.82e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HBA1—breast cancer	2.66e-06	2.82e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO1—breast cancer	2.64e-06	2.79e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS1—breast cancer	2.64e-06	2.79e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP17A1—breast cancer	2.64e-06	2.79e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO1—breast cancer	2.61e-06	2.77e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS1—breast cancer	2.61e-06	2.77e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTT1—breast cancer	2.6e-06	2.75e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ACHE—breast cancer	2.6e-06	2.75e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP2D6—breast cancer	2.59e-06	2.74e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—breast cancer	2.57e-06	2.71e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP2D6—breast cancer	2.56e-06	2.71e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CB—breast cancer	2.55e-06	2.7e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NCOA2—breast cancer	2.54e-06	2.69e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—breast cancer	2.53e-06	2.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NCOA2—breast cancer	2.52e-06	2.66e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ALB—breast cancer	2.47e-06	2.61e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—FASN—breast cancer	2.47e-06	2.61e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP17A1—breast cancer	2.46e-06	2.6e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—BCHE—breast cancer	2.46e-06	2.6e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ALB—breast cancer	2.45e-06	2.59e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—FASN—breast cancer	2.44e-06	2.58e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS1—breast cancer	2.44e-06	2.58e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO1—breast cancer	2.44e-06	2.58e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—BCHE—breast cancer	2.43e-06	2.57e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC5A5—breast cancer	2.43e-06	2.57e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC5A5—breast cancer	2.4e-06	2.54e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP2D6—breast cancer	2.39e-06	2.53e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—breast cancer	2.36e-06	2.5e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NCOA2—breast cancer	2.35e-06	2.48e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC2A1—breast cancer	2.34e-06	2.48e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NQO1—breast cancer	2.34e-06	2.48e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC2A1—breast cancer	2.32e-06	2.45e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NQO1—breast cancer	2.32e-06	2.45e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP3A4—breast cancer	2.29e-06	2.42e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ALB—breast cancer	2.28e-06	2.41e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—FASN—breast cancer	2.28e-06	2.41e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—BCHE—breast cancer	2.27e-06	2.4e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—breast cancer	2.27e-06	2.4e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP3A4—breast cancer	2.26e-06	2.39e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1B1—breast cancer	2.25e-06	2.38e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC5A5—breast cancer	2.24e-06	2.37e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—RAF1—breast cancer	2.23e-06	2.36e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1B1—breast cancer	2.22e-06	2.35e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—RAF1—breast cancer	2.21e-06	2.34e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—breast cancer	2.21e-06	2.33e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HSP90AA1—breast cancer	2.2e-06	2.33e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HSP90AA1—breast cancer	2.18e-06	2.31e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC2A1—breast cancer	2.16e-06	2.29e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NQO1—breast cancer	2.16e-06	2.29e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NCOA1—breast cancer	2.14e-06	2.27e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NCOA1—breast cancer	2.12e-06	2.24e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—STK11—breast cancer	2.11e-06	2.23e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP19A1—breast cancer	2.11e-06	2.23e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—breast cancer	2.11e-06	2.23e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP3A4—breast cancer	2.11e-06	2.23e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—STK11—breast cancer	2.09e-06	2.21e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP19A1—breast cancer	2.09e-06	2.21e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1B1—breast cancer	2.07e-06	2.19e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—RAF1—breast cancer	2.06e-06	2.18e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HSP90AA1—breast cancer	2.03e-06	2.15e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—breast cancer	2.02e-06	2.14e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NCOA1—breast cancer	1.98e-06	2.09e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—COMT—breast cancer	1.96e-06	2.08e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTP1—breast cancer	1.95e-06	2.07e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—STK11—breast cancer	1.95e-06	2.06e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP19A1—breast cancer	1.95e-06	2.06e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—COMT—breast cancer	1.94e-06	2.06e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTP1—breast cancer	1.93e-06	2.05e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HMOX1—breast cancer	1.93e-06	2.04e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ITPR1—breast cancer	1.92e-06	2.03e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HMOX1—breast cancer	1.91e-06	2.02e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ITPR1—breast cancer	1.9e-06	2.01e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—breast cancer	1.85e-06	1.96e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—breast cancer	1.83e-06	1.94e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—breast cancer	1.82e-06	1.92e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—COMT—breast cancer	1.81e-06	1.92e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTP1—breast cancer	1.8e-06	1.91e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—breast cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTM1—breast cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PLA2G4A—breast cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NCOR1—breast cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HMOX1—breast cancer	1.78e-06	1.88e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PLA2G4A—breast cancer	1.78e-06	1.88e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTM1—breast cancer	1.78e-06	1.88e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NCOR1—breast cancer	1.78e-06	1.88e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ITPR1—breast cancer	1.77e-06	1.88e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPX1—breast cancer	1.72e-06	1.82e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—breast cancer	1.71e-06	1.8e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1A1—breast cancer	1.7e-06	1.8e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPX1—breast cancer	1.7e-06	1.8e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ERCC2—breast cancer	1.69e-06	1.79e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1A1—breast cancer	1.69e-06	1.78e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—breast cancer	1.68e-06	1.77e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ERCC2—breast cancer	1.67e-06	1.77e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—breast cancer	1.67e-06	1.76e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PLA2G4A—breast cancer	1.66e-06	1.75e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTM1—breast cancer	1.66e-06	1.75e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NCOR1—breast cancer	1.66e-06	1.75e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—breast cancer	1.65e-06	1.75e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—MTHFR—breast cancer	1.59e-06	1.68e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPX1—breast cancer	1.59e-06	1.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MTHFR—breast cancer	1.57e-06	1.66e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1A1—breast cancer	1.57e-06	1.66e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ERCC2—breast cancer	1.56e-06	1.65e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—breast cancer	1.56e-06	1.65e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MTHFR—breast cancer	1.46e-06	1.55e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CAV1—breast cancer	1.46e-06	1.55e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CAV1—breast cancer	1.45e-06	1.53e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—breast cancer	1.36e-06	1.44e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CAV1—breast cancer	1.35e-06	1.43e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CG—breast cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CG—breast cancer	1.32e-06	1.4e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—breast cancer	1.27e-06	1.34e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CG—breast cancer	1.23e-06	1.3e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CD—breast cancer	1.17e-06	1.24e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CD—breast cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALB—breast cancer	1.16e-06	1.22e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALB—breast cancer	1.15e-06	1.21e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NOS3—breast cancer	1.11e-06	1.17e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NOS3—breast cancer	1.1e-06	1.16e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CD—breast cancer	1.08e-06	1.14e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALB—breast cancer	1.07e-06	1.13e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CB—breast cancer	1.02e-06	1.08e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NOS3—breast cancer	1.02e-06	1.08e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—breast cancer	1.01e-06	1.07e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CB—breast cancer	1.01e-06	1.07e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—breast cancer	1e-06	1.06e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CB—breast cancer	9.43e-07	9.97e-06	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—breast cancer	9.34e-07	9.88e-06	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—breast cancer	8.83e-07	9.34e-06	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—breast cancer	8.74e-07	9.24e-06	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—breast cancer	8.15e-07	8.61e-06	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—breast cancer	6.23e-07	6.59e-06	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—breast cancer	6.17e-07	6.52e-06	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—breast cancer	5.75e-07	6.08e-06	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—breast cancer	5.09e-07	5.38e-06	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—breast cancer	5.04e-07	5.33e-06	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—breast cancer	4.69e-07	4.96e-06	CbGpPWpGaD
